Abstract Severe coronavirus disease 2019 (COVID-19) is characterized by systemic hyper-
inflammation, acute respiratory distress syndrome, and multiple organ failure. Cytokine …

Objective Infection with the novel coronavirus SARS–CoV‐2 triggers severe illness with high
mortality in a subgroup of patients. Such a critical course of COVID‐19 is thought to be …

In its most severe form, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the
virus that causes coronavirus disease 2019 (COVID-19), leads to a life-threatening …

Background Tocilizumab, a monoclonal antibody directed against the interleukin-6 receptor,
has been proposed to mitigate the cytokine storm syndrome associated with severe COVID …

The description of a so-called cytokine storm in patients with COVID-19 has prompted
consideration of anti-cytokine therapies, particularly interleukin-6 antagonists. However …

Cytokine storm is an acute hyperinflammatory response that may be responsible for critical
illness in many conditions including viral infections, cancer, sepsis, and multi-organ failure …

We described three critically ill patients with coronavirus disease 2019 (COVID-19) in
Wuhan, China, featured with profound inflammation and treated with blood purification …

Many patients with severe COVID-19 rapidly progress to critical disease with refractory
hypoxemia requiring invasive mechanical ventilation (IMV). 1 Elevated levels of C reactive …

Objectives Severe systemic inflammation associated with some stages of COVID-19 and in
fatal cases led therapeutic agents developed or used frequently in Rheumatology being at …

Data suggest that interleukin (IL)-6 blockade could reduce mortality in severe COVID-19, yet
IL-6 is only modestly elevated in most patients. Chen et al. describe the role of soluble …